Lorlatinib | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Lorlatinib
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Lorlatinib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 5 Listed Suppliers, $ API Reference Price

5 API Suppliers
5 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

8 FDF Dossiers, 2 FDA Orange Book, 2 Europe, 2 Canada, 2 Australia

8 FDF Dossiers
2 FDA Orange Book
2 Europe
2 Canada
2 Australia

DIGITAL CONTENT

30 News #PharmaBuzz

30 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Regulatory FDF Prices, 5 Annual Reports

1 US Medicaid Prescriptions
2 Regulatory FDF Prices
5 Annual Reports

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

10 US Patents, 8 US Exclusivities, 6 Health Canada Patents

10 US Patents
8 US Exclusivities
6 Health Canada Patents

$ API Ref.Price (USD/KG) : 17,097 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 6Pfizer Canada ULC

filter Patent Reset all filters

6 All

01 22863892

02 22916605

03 22937257

filter Product Reset all filters

6 All

01 6LORLATINIB

filter Dosage Reset all filters

6 All

01 6TABLET

filter Exp Date Reset all filters

6 All

01 22033-02-20

02 22034-06-17

03 22036-07-27

Product Main Page

01

Pfizer Canada ULC

Lorlatinib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-02-20

Date Granted : 2016-08-30

Brand Name : LORBRENA

Patent Number : 2863892

Filing Date : 2013-02-20

Strength per Unit : 25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-02-20

Date Granted : 2016-08-30

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Pfizer Canada ULC

Lorlatinib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-06-17

Date Granted : 2018-04-24

Brand Name : LORBRENA

Patent Number : 2916605

Filing Date : 2014-06-17

Strength per Unit : 25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2034-06-17

Date Granted : 2018-04-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Pfizer Canada ULC

Lorlatinib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-02-20

Date Granted : 2016-08-30

Brand Name : LORBRENA

Patent Number : 2863892

Filing Date : 2013-02-20

Strength per Unit : 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-02-20

Date Granted : 2016-08-30

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Pfizer Canada ULC

Lorlatinib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-06-17

Date Granted : 2018-04-24

Brand Name : LORBRENA

Patent Number : 2916605

Filing Date : 2014-06-17

Strength per Unit : 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2034-06-17

Date Granted : 2018-04-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Pfizer Canada ULC

Lorlatinib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-07-27

Date Granted : 2022-06-14

Brand Name : LORBRENA

Patent Number : 2937257

Filing Date : 2016-07-27

Strength per Unit : 25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2036-07-27

Date Granted : 2022-06-14

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Pfizer Canada ULC

Lorlatinib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-07-27

Date Granted : 2022-06-14

Brand Name : LORBRENA

Patent Number : 2937257

Filing Date : 2016-07-27

Strength per Unit : 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2036-07-27

Date Granted : 2022-06-14

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!